

# 3rd Human Challenge Trials in Vaccine Development

February 6-7, 2020 - Oxford, United Kingdom

## Biosketch



**Andrew Catchpole BSc DPhil**

### Chief Scientist hVIVO

Andrew Catchpole first studied as a virologist at the University of Warwick before then further his education with postgraduate studies in influenza replication at Oxford University. Since then he has applied his scientific knowledge in a commercial setting. After working as part of a multidisciplinary R and D team developing nuclear medicine research tools at GE Healthcare he then returned to the field of virology to work for hVIVO, an industry-leading provider of human viral challenge studies. Andrew is now considered an expert in human viral challenge studies (controlled human infection studies) having played key roles in the development of influenza, RSV and hRV models at hVIVO. He has overseen the design and conduct of numerous antiviral and vaccine product efficacy studies and now works as Chief Scientist in the company providing both internal consultancy as well as advising hVIVO's clients and collaborators on challenge study design. In addition, he was PI on a recently successfully completed DARPA-sponsored research project to utilise the challenge model to identify human biomarkers and algorithms prognostic of influenza contagiousness.



IABS - Rue de la Vallée, 3 - 1204 Geneva - Switzerland  
Tel : +41 22 301 10 36 - [www.iabs.org](http://www.iabs.org) - [iabs@iabs.org](mailto:iabs@iabs.org)